ALT Progression-free Survival and Time to Next Intervention (Full Analysis Set). Panel A shows the Kaplan–Meier plot of the probability of imaging‑based progression‑free survival as assessed by blinded independent review among patients randomly assigned to the vorasidenib group as compared with those randomly assigned to the placebo group (full analysis set). The median time to disease progression or death is shown. Panel B shows the Kaplan–Meier plot of the probability of receipt of a next anticancer treatment or death among patients randomly assigned to the vorasidenib group as compared with those randomly assigned to the placebo group. The median time to the receipt of the next anticancer treatment is shown. In both panels, tick marks indicate censored data.

ALT Subgroup Analyses of Progression-free Survival and Time to the Next Intervention (Full Analysis Set). Panel A shows a forest plot of hazard ratios for disease progression or death in the analysis of imaging‑based progression‑free survival according to blinded independent review in key subgroups, and Panel B shows a forest plot of hazard ratios for the receipt of the next intervention or death. Subgroup analyses were based on stratification‑factor data as entered in the interactive Web‑response system. Frontal tumor location included frontal, frontoparietal, and frontotemporal locations, and nonfrontal tumor location included all other locations. In the analyses in both panels, the widths of the confidence intervals have not been adjusted for multiplicity. Thus, the confidence intervals should not be used to reject (or not reject) the effects of vorasidenib. NE denotes not estimated.